School of Healthcare Studies, Cardiff University, Ty Dewi Sant, Health Park, Cardiff CF14 4XN, United Kingdom.
Phys Ther. 2013 Jul;93(7):942-56. doi: 10.2522/ptj.20130032. Epub 2013 Mar 21.
Clinical intervention trials in people with Huntington disease (HD) have been limited by a lack of reliable and appropriate outcome measures.
The purpose of this study was to determine the reliability and minimal detectable change (MDC) of various outcome measures that are potentially suitable for evaluating physical functioning in individuals with HD.
This was a multicenter, prospective, observational study.
Participants with pre-manifest and manifest HD (early, middle, and late stages) were recruited from 8 international sites to complete a battery of physical performance and functional measures at 2 assessments, separated by 1 week. Test-retest reliability (using intraclass correlation coefficients) and MDC values were calculated for all measures.
Seventy-five individuals with HD (mean age=52.12 years, SD=11.82) participated in the study. Test-retest reliability was very high (>.90) for participants with manifest HD for the Six-Minute Walk Test (6MWT), 10-Meter Walk Test, Timed "Up & Go" Test (TUG), Berg Balance Scale (BBS), Physical Performance Test (PPT), Barthel Index, Rivermead Mobility Index, and Tinetti Mobility Test (TMT). Many MDC values suggested a relatively high degree of inherent variability, particularly in the middle stage of HD. Minimum detectable change values for participants with manifest HD that were relatively low across disease stages were found for the BBS (5), PPT (5), and TUG (2.98). For individuals with pre-manifest HD (n=11), the 6MWT and Four Square Step Test had high reliability and low MDC values.
The sample size for the pre-manifest HD group was small.
The BBS, PPT, and TUG appear most appropriate for clinical trials aimed at improving physical functioning in people with manifest HD. Further research in people with pre-manifest HD is necessary.
由于缺乏可靠且适当的评估指标,针对亨廷顿病(HD)患者的临床干预试验一直受到限制。
本研究旨在确定各种潜在适用于评估 HD 患者身体机能的评估指标的可靠性和最小可检测变化(MDC)。
这是一项多中心、前瞻性、观察性研究。
从 8 个国际站点招募处于前驱期和显性期(早期、中期和晚期)的 HD 患者,他们在 2 次评估中完成一系列身体表现和功能评估,间隔 1 周。所有评估指标的测试-重测信度(采用组内相关系数)和 MDC 值。
共有 75 名 HD 患者(平均年龄=52.12 岁,标准差=11.82)参与了这项研究。对于显性 HD 患者,6 分钟步行测试(6MWT)、10 米步行测试、计时“起立-行走”测试(TUG)、Berg 平衡量表(BBS)、体能测试(PPT)、巴氏指数、Rivermead 移动指数和 Tinetti 移动测试(TMT)的测试-重测信度非常高(>.90)。许多 MDC 值表明存在较大的固有变异性,尤其是在 HD 的中期。在显性 HD 患者中,BBS(5)、PPT(5)和 TUG(2.98)的 MDC 值相对较低。对于前驱期 HD 患者(n=11),6MWT 和四点步测试具有较高的可靠性和较低的 MDC 值。
前驱期 HD 患者的样本量较小。
BBS、PPT 和 TUG 似乎最适合旨在改善显性 HD 患者身体机能的临床试验。进一步研究前驱期 HD 患者非常必要。